Market Overview:
Alpha emitter therapies are used in the treatment of various types of cancers like prostate, breast and ovarian cancers. Alpha emitters like actinium-225 and bismuth-213 are directly attached to monoclonal antibodies that bind to cancer cells. They deliver a high dose of radioactivity selectively to the tumor cells while causing minimal damage to normal tissues in the vicinity.

Market key trends:
One of the major trends in the alpha emitter ... Read more

Alpha emitters are radioactive particles or isotopes that release alpha particles during radioactive decay. They are primarily used in targeted alpha therapy (TAT) for cancer treatment. In TAT, alpha emitter isotopes are attached to molecules that specifically target tumor cells. When internalized by cancer cells, alpha particles can damage DNA and induce cell death. Compared to other radiation therapy, TAT is more effective in treating cancers with minimal damage to surrounding healthy ... Read more

Alpha emitter therapy, also known as alpha radionuclide therapy, uses radioactive particles that emit alpha particles to treat cancer. These alpha emitters include radionuclides such as radium-223, actinium-225, and bismuth-213 that can be attached to carriers like antibodies, peptides, small molecules and delivered directly to the tumors to irradiate cancer cells from inside while sparing surrounding healthy tissues. This therapy holds promise for treating both primary cancers as well as ... Read more

The alpha emitter market comprises of alpha emitting isotopes which are used as therapeutic agents for cancer treatment. Alpha particles have high mass and positive charge, which makes them highly effective in damaging cancer cells. Alpha emitting isotopes such as radium-223 (Xofigo) and actinium-225 are majorly used to treat cancers such as prostate cancer, bone metastases and other cancers. The ability to effectively destroy cancer cells with minimum damage to surrounding healthy tissues ... Read more